Celgene, Bristol-Myers move to dismiss US antitrust claims over Thalomid, Revlimid
MLex Summary: Celgene and Bristol-Myers Squibb moved to dismiss claims that they illegally monopolized the market for Thalomid and Revlimid, saying that plaintiffs fail to show any sham litigation. “If plaintiffs’...To view the full article, register now.
Already a subscriber? Click here to view full article